Literature DB >> 18936646

The effect of a probiotic on hepatic steatosis.

Steven F Solga, Gillian Buckley, Jeanne M Clark, Alena Horska, Anna Mae Diehl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18936646      PMCID： PMC4539951          DOI： 10.1097/MCG.0b013e31816d920c

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


× No keyword cloud information.
  11 in total

1.  Is bacterial ash the flash that ignites NASH?

Authors:  G C Farrell
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

2.  Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis.

Authors:  S M Riordan; V M Duncombe; M C Thomas; A Nagree; T D Bolin; C J McIver; R Williams
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 3.  Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics.

Authors:  Steven F Solga; A M Diehl
Journal:  J Hepatol       Date:  2003-05       Impact factor: 25.083

Review 4.  Gut flora-based therapy in liver disease? The liver cares about the gut.

Authors:  Steven F Solga; Anna Mae Diehl
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

5.  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

Authors:  Lidia S Szczepaniak; Pamela Nurenberg; David Leonard; Jeffrey D Browning; Jason S Reingold; Scott Grundy; Helen H Hobbs; Robert L Dobbins
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08-31       Impact factor: 4.310

6.  Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us.

Authors:  Jeanne M Clark; Frederick L Brancati
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

Review 7.  Molecular assessment of intestinal microflora.

Authors:  G W Tannock
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

8.  Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

Authors:  Carmela Loguercio; Alessandro Federico; Concetta Tuccillo; Fulvia Terracciano; Mauro Valeriano D'Auria; Claudio De Simone; Camillo Del Vecchio Blanco
Journal:  J Clin Gastroenterol       Date:  2005-07       Impact factor: 3.062

9.  Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth.

Authors:  M Nazim; G Stamp; H J Hodgson
Journal:  Hepatogastroenterology       Date:  1989-10

10.  Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.

Authors:  Zhiping Li; Shiqi Yang; Huizhi Lin; Jiawen Huang; Paul A Watkins; Ann B Moser; Claudio Desimone; Xiao-yu Song; Anna Mae Diehl
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425
View more
  21 in total

Review 1.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

2.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 3.  Probiotics and liver disease.

Authors:  Vishal Sharma; Shashank Garg; Sourabh Aggarwal
Journal:  Perm J       Date:  2013

Review 4.  Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.

Authors:  Silvia Marinho Ferolla; Geyza Nogueira de Almeida Armiliato; Cláudia Alves Couto; Teresa Cristina Abreu Ferrari
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

Authors:  Giulia Paolella; Claudia Mandato; Luca Pierri; Marco Poeta; Martina Di Stasi; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

6.  Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.

Authors:  Gabriella V Hernandez; Victoria A Smith; Megan Melnyk; Matthew A Burd; Kimberly A Sprayberry; Mark S Edwards; Daniel G Peterson; Darin C Bennet; Rob K Fanter; Daniel A Columbus; Juan P Steibel; Hunter Glanz; Chad Immoos; Margaret S Rice; Tasha M Santiago-Rodriguez; Jason Blank; Jennifer J VanderKelen; Christopher L Kitts; Brian D Piccolo; Michael R La Frano; Douglas G Burrin; Magdalena Maj; Rodrigo Manjarin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-31       Impact factor: 4.052

Review 7.  Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Keiichiro Sugimoto; Hiroshi Inui; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 8.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

Review 9.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 10.  Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded?

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader
Journal:  Diabetes Care       Date:  2010-10       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.